Navigation Links
Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research
Date:11/3/2008

fit into the larger context of the MJFF portfolio.

Rapid Response Innovation Awards, An Edmond J. Safra Core Program for PD Research

Total available funding: $2 million

No deadline; applications accepted at any time

Rapid Response Innovation Awards provide up to $75,000 for projects with little to no existing preliminary data, but with potential to significantly impact understanding or treatment of Parkinson's disease. MJFF is eager to fund high-risk, high-reward projects tackling critical scientific roadblocks to open new avenues for PD therapy development. Research proposals may be submitted at any time and funding decisions are made within six weeks of receiving the application.

Target Validation, An Edmond J. Safra Core Program for PD Research

Total available funding: $2 million

Deadline: 6 p.m. ET, Tuesday, January 6, 2009

Funding anticipated: May 2009

Target Validation provides awards of up to $250,000 to validate the therapeutic potential of scientific discoveries and push them one step closer to the clinic. While research continues to identify new genetic, cellular and biological targets for therapeutic intervention to benefit PD patients, the translation of these discoveries into practical treatments requires additional applied work. Target Validation funds this work with the ultimate goal of 'de-risking' potential investment in the most promising targets by biotech and pharmaceutical companies, who are generally best-suited to carry promising therapies forward into the clinic.

Clinical Intervention Awards, An Edmond J. Safra Core Program for PD Research Total available funding: $3 million

An Edmond J. Safra Core Program for PD Research

Deadline: 6 p.m. ET, Thursday, March 12, 2009

Funding anticipated: July 2009

The Clinical Intervention Awards drive clinical intervention trials of promising therapeutic approaches with potential to significantly improve the tr
'/>"/>

SOURCE The Michael J. Fox Foundation for Parkinson's Research
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Calif. , May 21, 2013 Abaxis, ... blood analysis systems, announced today that Martin ... at the Stifel Annual Dental & Veterinary Conference on ... conference will be held at Le Parker Meridien Hotel ... About Abaxis Abaxis develops, manufactures, markets ...
(Date:5/21/2013)... YORK , May 21, 2013 /PRNewswire/ ... research report is available in its catalogue: ... Regulatory and Reimbursement Scenario for Medical Devices ... http://www.reportlinker.com/p01188015/Changing-Regulatory-and-Reimbursement-Scenario-for-Medical-Devices-in-the-US-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging   Changing ... in the US Market   ...
(Date:5/21/2013)... MONROVIA, Calif. , May 21, 2013 ... leading developer, manufacturer and marketer of minimally invasive ophthalmic ... upcoming investor conferences to review the Company,s recent financial ... STAAR Surgical will present at the 38 ... Boston at the Westin Waterfront ...
Breaking Medicine Technology:Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4STAAR Surgical To Present At Upcoming Investor Conferences 2
... Poster 16LB -- Late-breaking Novo Nordisk (NVO) extension data presented today ... that once-daily Victoza ® in combination with metformin produced sustained and significantly ... ® plus metformin at 52 weeks. , ... Key findings from the study include: , ...
... JACKSONVILLE, Fla. , June 28 ... of its SurgiSteer™ laparoscopic instruments.  Developed from licensed ... will exploit single port laparoscopic surgery with its ... and Endo Scissors, available in both free and ...
Cached Medicine Technology:New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 2New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 3New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 4New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 5New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 6New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 7Steerable Technologix LLC Announces Release of SurgiSteer Laparoscopic Instruments 2
(Date:5/21/2013)... Dallas-based TopMD™ Skin Care today announced results of ... of their flagship product, CLn® BodyWash for ... in the May/June 2013 issue of Pediatric Dermatology ... Cleanser Shows Clinical Response and Excellent Acceptability in the ... consistent use of the product by 18 pediatric patients ...
(Date:5/21/2013)... Dimensional Insight, a developer of business intelligence ... Health System, a 275-bed hospital based in Cumberland, ... help it analyze its data more quickly. Western Maryland ... through Dimensional Insight’s recently announced partnership with Premier ... has massive amounts of data in disparate systems, such ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Romio ... people with trusted services & businesses, announced today that ... Emergency Medical Care. , Emergency Medical Care is located ... services 24 hours a day. The guarantee of ... is a promising resource for the neighborhood and a ...
(Date:5/21/2013)... Reporter , , MONDAY, May 20 (HealthDay News) -- Young ... a higher risk of getting into car crashes, but ... missed sleep on weekends puts them in even greater ... is another challenge to adolescents that comes with lack ... founder of the Center for Injury Research and Prevention ...
(Date:5/21/2013)... TUESDAY, May 21 (HealthDay News) -- Racial disparities exist ... hospitals in the United States, according to a large ... undergo surgery as part of their initial treatment, researchers ... whites to have surgery in the early stages of ... for stage 1 and stage 2 disease than white ...
Breaking Medicine News(10 mins):Health News:Peer-Reviewed Article Shows CLn® BodyWash an Effective Solution for Children with Eczema 2Health News:Peer-Reviewed Article Shows CLn® BodyWash an Effective Solution for Children with Eczema 3Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 2Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 3Health News:Romio Announces Mini Video Series Featuring Local Business Emergency Medical Care 2Health News:Weekend 'Catch-Up' Sleep May Cut Young Drivers' Crash Risk 2Health News:Racial Disparities Seen in U.S. Lung Cancer Treatment 2
... NY) For the third time in four months, the ... National Institutes of Health (NIH) has awarded Albert Einstein College ... helping people infected with multidrug-resistant tuberculosis (MDR-TB). Taken ... latest awardee Neel Gandhi, M.D. , assistant professor ...
... July 27, 2010 Researchers at UT Southwestern Medical ... doses of corticosteroids given repeatedly over several weeks may ... affects more than 1 million people in the U.S. ... sometimes use illegally to bulk up muscle, corticosteroids are ...
... By Madonna Behen HealthDay Reporter , MONDAY, July ... Administration has required that all epilepsy drugs bear a warning ... doctors report that only certain medications may increase the risk ... the findings and say the paper raises more questions than ...
... such as everolimus that target the protein mTOR are used ... respond to the treatment. A team of researchers, led by ... has now identified a way to help predict which patients ... that human cancer cells with mutations in the PIK3CA gene ...
... major research company affiliated with the University of Colorado ... the University of Colorado,s Anschutz Medical Campus to more ... laboratory to the patient. CPC, formally known as the ... Incorporated building across the street from the campus on ...
... Society for Radiation Oncology (ASTRO) has named N. Reed ... diagnostic radiology, as its 2010 Honorary Member, which is ... researchers and leaders in disciplines other than radiation oncology, ... with this honor during the Awards Ceremony at ASTRO,s ...
Cached Medicine News:Health News:Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection 2Health News:Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection 3Health News:Researchers uncover biological rationale for why intensive lupus treatment works 2Health News:Researchers uncover biological rationale for why intensive lupus treatment works 3Health News:Not All Epilepsy Drugs Raise Suicide Risk: Study 2Health News:Not All Epilepsy Drugs Raise Suicide Risk: Study 3Health News:University of Colorado joins forces with major research affiliate 2Health News:ASTRO names radiologist, ABR president Society's 2010 Honorary Member 2
... is a state-of-the-art hair reduction and ... specially designed for use within a ... features and economy in a single ... treatment of unwanted hair, photo rejuvenation ...
... perfect mix of powerful, versatile, and innovative ... Palomar StarLux® Pulsed Light and Laser System.,With ... compact base unit so theres no ... treatments., You can choose among Laser, Intense ...
Perfect for physicians who prefer a Heavier and Longer tubing, permitting them maximum access around the OR table. 12 feet in length Sizes availabe to fit any vacuum canisters...
... Pump provides optimum flow rate ... Operates on any voltage worldwide. ... safety Interlock and easy load ... Double Spike Tubing, Dual Pneumatic ...
Medicine Products: